May 16, 2024
You are here:  Home  >  Health Care & Life Science  >  Current Article

MannKind stock slumps despite cashing in on United deal


MannKind shares tumbled more than 8 percent in midday trading April 1, despite an announcement that the company had received the first milestone payment in its deal with United Therapeutics. United paid $12.5 million to Westlake Village-based MannKind for its inhalable dry powder version of United’s high blood pressure therapy treprostinil. The new delivery mechanism…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.